Premium
Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II
Author(s) -
Davis Timothy M. E.,
Kauhanen Jane,
Davis Wendy A.
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13569
Subject(s) - medicine , vaccination , pneumococcal polysaccharide vaccine , diabetes mellitus , pneumonia , type 2 diabetes , pneumococcal vaccine , pharmacotherapy , pneumococcal pneumonia , community acquired pneumonia , pediatrics , streptococcus pneumoniae , intensive care medicine , pneumococcal disease , immunology , antibiotics , endocrinology , microbiology and biotechnology , biology
Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5‐yearly doses. In 1465 representative community‐based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self‐reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub‐optimal coverage.